Carfilzomib for relapsed and refractory multiple myeloma

Autor: Groen K, van de Donk NWCJ, Stege CAM, Zweegman S, Nijhof IS

Publikováno v: Cancer Management and Research, Vol Volume 11, Pp 2663-2675 (2019)

K Groen, NWCJ van de Donk, CAM Stege, S Zweegman, IS Nijhof Department of Hematology, VU University Medical Center, Amsterdam, Netherlands Abstract: Although the prognosis of multiple myeloma (MM) patients has dramatically improved during recent year

Externí odkaz: https://doaj.org/article/90fe6e5765eb4678aa10dcf4ac8bad8d

Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.

Autor: Lin Y; Department of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address: lin.yi@mayo.edu., Qiu L; National Clinical Research Center for Blood Diseases and State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Pekin Union Medical College, Tianjin, China., Usmani S; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Joo CW; Department of Medical Oncology, National University Cancer Institute, Singapore., Costa L; Department of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA., Derman B; Department of Hematology and Oncology, University of Chicago, Chicago, IL, USA., Du J; Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Navy Medical University, Shanghai, China., Einsele H; Department of Internal Medicine II, University Hospital, Wurzburg, Germany., Fernandez de Larrea C; Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Hajek R; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic; Department of Hematooncology, Faculty of Medicine, University Ostrava, Ostrava, Czech Republic., Ho PJ; Institute of Hematology, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia., Kastritis E; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Martinez-Lopez J; Hospital Universitario 12 de Octubre, Department of Medicine, Complutense University, CNIO, Madrid, Spain., Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain., Mikhael J; Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA., Moreau P; Department of Hematology, University Hospital of Nantes, Nantes, France., Nagarajan C; Department of Haematology, Singapore General Hospital, Singapore., Nooka A; Winship Cancer Institute of Emory University, Atlanta, GA, USA., O'Dwyer M; Department of Medicine and Department of Haematology, National University of Ireland, Galway, Ireland., Schjesvold F; Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway., Sidana S; School of Medicine, Stanford University, San Francisco, CA, USA., van de Donk NW; Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands., Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Zweegman S; Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands., Raje N; Department of Medicine, Harvard University, Cambridge, MA, USA., Otero PR; Department of Hematology, Cancer Center Clinica Universidad de Navarra, Pamplona, Navarra, Spain., Anderson LD Jr; Simmons Comprehensive Cancer Center, Dallas, TX, USA; University of Texas Southwestern Medical Center, Dallas, TX, USA., Kumar S; Department of Hematology, Mayo Clinic, Rochester, MN, USA., Martin T; Department of Hematology, University of California, San Francisco, CA, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Aug; Vol. 25 (8), pp. e374-e387. Date of Electronic Publication: 2024 May 28.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Autor: Moreau P; Hematology, University Hospital Hôtel-Dieu, Nantes, France. Electronic address: philippe.moreau@chu-nantes.fr., Attal M; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Hulin C; Department of Hematology, Hopital Haut Leveque, University Hospital Bordeaux, Bordeaux, France., Arnulf B; Immuno-Hématologie, Hopital Saint Louis, Paris, France., Belhadj K; Hematology, Hopital Henri Mondor, Creteil, France., Benboubker L; Hôpital de Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France., Béné MC; Hematology Biology, University Hospital Hôtel Dieu, Nantes, France., Broijl A; Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands., Caillon H; Biochemistry Laboratory, Hospital of Nantes, Nantes, France., Caillot D; Hôpital Du Bocage, Centre Hospitalier Universitaire Dijon, Dijon, France., Corre J; Unite de Genomique du Myelome, Institut universitaire du cancer de Toulouse Oncopole, Toulouse, France., Delforge M; Universitaire Ziekenhuizen Leuven, Leuven, Belgium., Dejoie T; Biochemistry Laboratory, Hospital of Nantes, Nantes, France., Doyen C; Centre Hospitalier Universitaire UCL Namur-site Godinne, Yvoir, Belgium., Facon T; Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France., Sonntag C; Hopital Hautepierre, Strasbourg, France., Fontan J; Jean Minjoz Hôpital, Besancon, France., Garderet L; Team Proliferation and Differentiation of Stem Cells, Centre de Recherche Saint-Antoine, Inserm, Sorbonne Université, Paris, France; Département d'Hématologie et de Thérapie Cellulaire, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France., Jie KS; Zuyderland Medisch Centrum, Sittard, Netherlands., Karlin L; Service d'Hématologie Clinique, Centre Hospitalier Lyon-Sud, Lyon, France., Kuhnowski F; Institut Curie Paris, Paris, France., Lambert J; Biostatistical Department, Hôpital Saint Louis, Paris, France., Leleu X; Hôpital la Milétrie, Centre Hospitalier Universitaire de Poitiers, Poitiers, France., Lenain P; Centre de Lutte Contre le Cancer-Centre Henri Becquerel, Rouen, France., Macro M; Centre Hospitalier Universitaire de Caen, Caen, France., Mathiot C; Institut Français de la Mode, Paris, France., Orsini-Piocelle F; Centre Hospitalier Annecy Genevois, Pringy, France., Perrot A; Hematology Department, Vandoeuvre Les Nancy, University Hospitals Nancy, France., Stoppa AM; Institut Paoli Calmettes, Marseille, France., van de Donk NW; Department of Hematology, University Medical Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Wuilleme S; Hematology Biology, University Hospital Hôtel Dieu, Nantes, France., Zweegman S; Department of Hematology, University Medical Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Kolb B; Hôpital Robert Debré, Centre Hospitalier Universitaire de Reims, Reims, France., Touzeau C; Centre Hospitalier Universitaire de Nantes, Nantes, France., Roussel M; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Tiab M; Centre Hospitalier Départemental Vendée, La Roche sur Yon, France., Marolleau JP; Centre Hospitalier Universitaire Amiens Sud, Amiens, France., Meuleman N; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Vekemans MC; Cliniques Universitaires Saint-Luc, Brussels, Belgium., Westerman M; Northwest Clinics, Alkmaar, Netherlands., Klein SK; Meander Medical Center, Amersfoort, Netherlands., Levin MD; Albert Schweitzer Hospital, Dordrecht, Netherlands., Fermand JP; Service d'Immuno-Hématologie, Département d'Immunologie Clinique, Inserm and Intergroupe Francophone du Myélome, Hôpital Saint-Louis, Paris, France., Escoffre-Barbe M; Hôpital de Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France., Eveillard JR; Hôpital A. Morvan, Centre Hospitalier Universitaire de Brest, Brest, France., Garidi R; Hospital Center de Saint-Quentin, Saint Quentin, France., Ahmadi T; Genmab US, Inc, Princeton, NJ, USA., Zhuang S; Janssen Research & Development, Raritan, NJ, USA., Chiu C; Janssen Research & Development, Spring House, PA, USA., Pei L; Janssen Research & Development, Raritan, NJ, USA., de Boer C; Janssen Research & Development, LLC, Leiden, Netherlands., Smith E; Janssen Research & Development, LLC, High Wycombe, UK., Deraedt W; Janssen Research & Development, Beerse, Belgium., Kampfenkel T; Janssen Research & Development, LLC, Leiden, Netherlands., Schecter J; Janssen Research & Development, Raritan, NJ, USA., Vermeulen J; Janssen Research & Development, LLC, Leiden, Netherlands., Avet-Loiseau H; Unite de Genomique du Myelome, Institut universitaire du cancer de Toulouse Oncopole, Toulouse, France., Sonneveld P; Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands.

Publikováno v: Lancet (London, England) [Lancet] 2019 Jul 06; Vol. 394 (10192), pp. 29-38. Date of Electronic Publication: 2019 Jun 03.

Identifying Educational Needs and Practice Gaps of European Hematologists and Hematology Nurses in the Treatment and Management of Multiple Myeloma.

Autor: Murray S; AXDEV Group Inc., Brossard, QC, Canada., Mohty M; Hematology and Cellular Therapy Department, Hospital St Antoine, University Pierre & Marie Curie, Paris, France., Peloquin S; AXDEV Group Inc., Brossard, QC, Canada., Van de Donk NW; Department of Haematology, VU University Medical Center, Amsterdam, the Netherlands., Leitão S; Janssen-Cilag Farmacêutica, Barcarena, Portugal., Labbé S; AXDEV Group Inc., Brossard, QC, Canada., West S; Haemato-Oncology Unit, Royal Mardsen Hospital, London, UK., Hofstädter-Thalmann E; Janssen-Cilag, Pharma GmbH, Vienna, Austria., Sonneveld P; Department of Haematology, Erasmus MC, Rotterdam, the Netherlands.

Publikováno v: HemaSphere [Hemasphere] 2018 Mar 01; Vol. 2 (2), pp. e33. Date of Electronic Publication: 2018 Mar 01 (Print Publication: 2018).

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma.

Autor: Franssen LE; Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., Roeven MWH; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Hobo W; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Doorn R; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Oostvogels R; Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., Falkenburg JHF; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., van de Donk NW; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., Kester MGD; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Fredrix H; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Westinga K; Cell Therapy Facility, University Medical Center Utrecht, Utrecht, The Netherlands., Slaper-Cortenbach I; Cell Therapy Facility, University Medical Center Utrecht, Utrecht, The Netherlands., Spierings E; Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Kersten MJ; Department of Hematology, Amsterdam Medical Center, Amsterdam, The Netherlands., Dolstra H; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Mutis T; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., Schaap N; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Lokhorst HM; Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2017 Oct; Vol. 52 (10), pp. 1378-1383. Date of Electronic Publication: 2017 Jun 05.